HRP20171320T1 - Terc-butil n-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorofenil}etil]-l-alaninat ili njegova sol, hidrat ili solvat - Google Patents

Terc-butil n-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorofenil}etil]-l-alaninat ili njegova sol, hidrat ili solvat Download PDF

Info

Publication number
HRP20171320T1
HRP20171320T1 HRP20171320TT HRP20171320T HRP20171320T1 HR P20171320 T1 HRP20171320 T1 HR P20171320T1 HR P20171320T T HRP20171320T T HR P20171320TT HR P20171320 T HRP20171320 T HR P20171320T HR P20171320 T1 HRP20171320 T1 HR P20171320T1
Authority
HR
Croatia
Prior art keywords
compound
preparation
treatment
cancer
disease
Prior art date
Application number
HRP20171320TT
Other languages
English (en)
Inventor
Stéphane PINTAT
Stephen John Davies
David Festus Charles Moffat
Original Assignee
Macrophage Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1218640.9A external-priority patent/GB201218640D0/en
Priority claimed from GB201306881A external-priority patent/GB201306881D0/en
Application filed by Macrophage Pharma Limited filed Critical Macrophage Pharma Limited
Publication of HRP20171320T1 publication Critical patent/HRP20171320T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (9)

1. Spoj koji je terc-butil N-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2H)-il]-3,5-difluorofenil}etil]-L-alaninat ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat.
2. Farmaceutski pripravak koji sadrži spoj prema zahtjevu 1 zajedno s jednim ili više farmaceutski prihvatljivih nosača i/ili pomoćnih tvari.
3. Spoj prema zahtjevu 1 ili pripravak prema zahtjevu 2 za primjenu u načinu liječenja ljudskog ili životinjskog organizma pomoću terapije.
4. Spoj prema zahtjevu 1 ili pripravak prema zahtjevu 2 za primjenu u inhibiciji djelovanja enzima p38 MAP kinaze in vitro ili in vivo.
5. Spoj ili pripravak za primjenu prema zahtjevu 4, naznačen time, što se spoj ili pripravak koristi za prevenciju ili liječenje autoimune ili upalne bolesti.
6. Spoj ili pripravak za primjenu prema zahtjevu 4 ili zahtjevu 5, naznačen time, što se spoj ili pripravak koristi za prevenciju ili liječenje reumatoidnog artritisa, psorijatičnog artritisa, dijabetesa tipa 1, astme, upalne bolesti crijeva, sistemskog eritemskog lupusa, upale koja prati zarazne bolesti, psorijaze, Crohnove bolesti, ulceroznog kolitisa, kronične opstruktivne plućne bolesti, multiple skleroze, atopijskog dermatitisa ili transplantacijske bolesti.
7. Spoj ili pripravak za primjenu prema zahtjevu 4, naznačen time, što se spoj ili pripravak koristi za liječenje bolesti proliferacije stanica.
8. Spoj ili pripravak za primjenu prema zahtjevu 4 ili zahtjevu 7, naznačen time, što se spoj ili pripravak koristi za liječenje raka.
9. Spoj ili pripravak za primjenu prema zahtjevu 4, zahtjevu 7 ili zahtjevu 8, naznačen time, što se spoj ili pripravak koristi za liječenje raka dojke, raka jajnika, raka gušterače, raka pluća, raka debelog crijeva, raka bubrega, limfoma ili melanoma.
HRP20171320TT 2012-10-17 2017-08-31 Terc-butil n-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorofenil}etil]-l-alaninat ili njegova sol, hidrat ili solvat HRP20171320T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1218640.9A GB201218640D0 (en) 2012-10-17 2012-10-17 Chemical compounds
GB201306881A GB201306881D0 (en) 2013-04-16 2013-04-16 Chemical compounds
PCT/GB2013/052689 WO2014060742A1 (en) 2012-10-17 2013-10-15 Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof
EP13783363.8A EP2909175B1 (en) 2012-10-17 2013-10-15 Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof

Publications (1)

Publication Number Publication Date
HRP20171320T1 true HRP20171320T1 (hr) 2017-10-20

Family

ID=49488610

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20171320TT HRP20171320T1 (hr) 2012-10-17 2017-08-31 Terc-butil n-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorofenil}etil]-l-alaninat ili njegova sol, hidrat ili solvat
HRP20191874TT HRP20191874T1 (hr) 2012-10-17 2019-10-15 N-[2-2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorofenil}etil]-l-alanin i njegov terbutil ester

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20191874TT HRP20191874T1 (hr) 2012-10-17 2019-10-15 N-[2-2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorofenil}etil]-l-alanin i njegov terbutil ester

Country Status (27)

Country Link
US (3) US9388136B2 (hr)
EP (2) EP3222616B1 (hr)
JP (2) JP6260975B2 (hr)
KR (1) KR102164536B1 (hr)
CN (2) CN104781235B (hr)
AU (1) AU2013333636B2 (hr)
BR (1) BR112015008167B1 (hr)
CA (1) CA2888928C (hr)
CY (2) CY1119080T1 (hr)
DK (2) DK2909175T3 (hr)
ES (2) ES2743768T3 (hr)
HK (1) HK1211028A1 (hr)
HR (2) HRP20171320T1 (hr)
HU (2) HUE046132T2 (hr)
IL (2) IL237863B (hr)
IN (1) IN2015DN02721A (hr)
LT (1) LT3222616T (hr)
MX (1) MX364782B (hr)
NZ (1) NZ706717A (hr)
PL (2) PL2909175T3 (hr)
PT (2) PT3222616T (hr)
RS (2) RS56184B1 (hr)
RU (1) RU2676329C2 (hr)
SG (2) SG11201502515VA (hr)
SI (2) SI2909175T1 (hr)
WO (1) WO2014060742A1 (hr)
ZA (1) ZA201501958B (hr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56184B1 (sr) * 2012-10-17 2017-11-30 Macrophage Pharma Ltd Terc-butil n-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorofenil}etil]-l-alaninat ili njegova so, hidrat ili solvat
GB201713975D0 (en) * 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
SI1474395T1 (sl) * 2002-02-12 2008-02-29 Smithkline Beecham Corp Nikotinamidni derivati, uporabni kot inhibitorji p38
PL372427A1 (en) 2002-03-14 2005-07-25 Bayer Healthcare Ag Monocyclic aroylpyridinones as antiinflammatory agents
JP2008542196A (ja) 2005-05-05 2008-11-27 クロマ セラピューティクス リミテッド カルボキシルエステラーゼにより加水分解可能なアルファアミノ酸エステル−薬剤複合体
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
GB0608837D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of MAP kinase
GB0608823D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of P13 kinase
GB0608821D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd DHFR enzyme inhibitors
AU2007246869B2 (en) 2006-05-04 2012-10-18 Macrophage Pharma Limited p38 MAP kinase inhibitors
GB0608855D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of MAP kinase enzymes
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
EP2079743B1 (en) 2006-10-25 2012-01-25 Chroma Therapeutics Limited Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
GB0621203D0 (en) 2006-10-25 2006-12-06 Chroma Therapeutics Ltd PLK inhibitors
US8962825B2 (en) 2006-10-30 2015-02-24 Glaxosmithkline Intellectual Property Development Limited Hydroxamates as inhibitors of histone deacetylase
ES2372707T3 (es) 2006-11-01 2012-01-25 Chroma Therapeutics Limited Inhibidores de la ikk-beta serina-treonina proteína quinasa.
US8106091B2 (en) 2006-11-01 2012-01-31 Chroma Therapeutics Ltd. Inhibitors of IKK-beta serine-threonine protein kinase
JP2011503042A (ja) * 2007-11-07 2011-01-27 クロマ セラピューティクス リミテッド p38MAPキナーゼ阻害剤
ES2427892T3 (es) * 2008-02-29 2013-11-04 Chroma Therapeutics Limited Inhibidores de MAP quinasa p38
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
WO2009130434A1 (en) 2008-04-23 2009-10-29 Chroma Therapeutics Ltd. INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE
GB0807451D0 (en) 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
EA201001708A1 (ru) 2008-04-26 2011-06-30 Хрома Терапьютикс Лтд. Замещённые тиофенкарбоксамиды их применение в качестве ингибиторов ikk-бета серин-треонин протеинкиназ
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB0907120D0 (en) 2009-04-24 2009-06-03 Chroma Therapeutics Ltd Inhibitors of IKK-ß serine-threonine protein kinase
GB201009853D0 (en) 2010-06-11 2010-07-21 Chroma Therapeutics Ltd HSP90 inhibitors
GB201021467D0 (en) 2010-12-17 2011-02-02 Chroma Therapeutics Ltd Imaging agents
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
RS56184B1 (sr) * 2012-10-17 2017-11-30 Macrophage Pharma Ltd Terc-butil n-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorofenil}etil]-l-alaninat ili njegova so, hidrat ili solvat

Also Published As

Publication number Publication date
JP2018048160A (ja) 2018-03-29
AU2013333636B2 (en) 2017-11-23
RS59458B1 (sr) 2019-11-29
CN106496106A (zh) 2017-03-15
KR102164536B1 (ko) 2020-10-12
IL256560A (en) 2018-02-28
EP2909175B1 (en) 2017-06-07
CA2888928C (en) 2020-05-26
MX364782B (es) 2019-05-07
CA2888928A1 (en) 2014-04-24
US20160297760A1 (en) 2016-10-13
PT2909175T (pt) 2017-09-13
RU2676329C2 (ru) 2018-12-28
PL2909175T3 (pl) 2017-10-31
HRP20191874T1 (hr) 2020-01-10
CN104781235B (zh) 2016-12-21
MX2015004368A (es) 2015-06-10
RS56184B1 (sr) 2017-11-30
ZA201501958B (en) 2016-01-27
KR20150067376A (ko) 2015-06-17
CY1122194T1 (el) 2020-11-25
US9896417B2 (en) 2018-02-20
EP3222616B1 (en) 2019-07-17
AU2013333636A1 (en) 2015-04-09
LT3222616T (lt) 2019-09-10
IN2015DN02721A (hr) 2015-09-04
ES2743768T3 (es) 2020-02-20
PT3222616T (pt) 2019-09-26
HUE035525T2 (en) 2018-05-28
CN106496106B (zh) 2019-05-10
NZ706717A (en) 2018-02-23
EP3222616A1 (en) 2017-09-27
EP2909175A1 (en) 2015-08-26
PL3222616T3 (pl) 2019-12-31
SI2909175T1 (sl) 2017-08-31
RU2015115213A (ru) 2016-12-10
IL256560B (en) 2019-07-31
HK1211028A1 (en) 2016-05-13
WO2014060742A1 (en) 2014-04-24
US10370332B2 (en) 2019-08-06
SG11201502515VA (en) 2015-05-28
DK3222616T3 (da) 2019-08-19
US20180127371A1 (en) 2018-05-10
US9388136B2 (en) 2016-07-12
JP6260975B2 (ja) 2018-01-17
SG10201708166SA (en) 2017-11-29
JP2015534974A (ja) 2015-12-07
JP6464244B2 (ja) 2019-02-06
BR112015008167A2 (pt) 2017-07-04
CY1119080T1 (el) 2018-01-10
IL237863B (en) 2018-06-28
DK2909175T3 (en) 2017-08-14
BR112015008167B1 (pt) 2020-11-17
SI3222616T1 (sl) 2019-10-30
CN104781235A (zh) 2015-07-15
ES2635240T3 (es) 2017-10-03
HUE046132T2 (hu) 2020-02-28
US20150246883A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
JP2017519027A5 (hr)
MX2015002044A (es) Pirazolil-ureas como inhibidores de quinasa.
JP2018507249A5 (hr)
MX2021001583A (es) Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso.
EA201790228A1 (ru) Композиции и способы получения пиримидиновых и пиридиновых соединений с btk ингибирующей активностью
MD4490B1 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
NZ766530A (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
GEP201706778B (en) Pyridinyl and fused pyridinyl triazolone derivatives
MX2019007057A (es) Composiciones de adenovirus.
HRP20171320T1 (hr) Terc-butil n-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorofenil}etil]-l-alaninat ili njegova sol, hidrat ili solvat
EA201401353A1 (ru) Биомаркеры для определения эффективной ответной реакции на лечение пациентов с гепатоцеллюлярной карциномой (гцк)
JP2015519396A5 (hr)
RU2018122953A (ru) Новые производные диаминопиридина
JP2015506352A5 (hr)
JP2015534974A5 (hr)
JP2015520744A5 (hr)
Lin et al. Identification of novel 7-amino-5-methyl-1, 6-naphthyridin-2 (1H)-one derivatives as potent PI3K/mTOR dual inhibitors
ES2498521A1 (es) Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad
JP2014240383A5 (hr)
Karshieva et al. Mesenchymal stem cells as an antitumor therapy tool
Lyman et al. Statement of retraction: Hongying Lv, Qicai Li, Wengsheng Qiu, Jinyu Xiang, Hongjun Wei, Hua Liang, Aihua Sui and Jun Liang" Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer"
黄慧琳 et al. Oridonin promotes Fbw7-mediated turnover of c-Myc: targeting oncogene addiction
Rombaut et al. Long non-coding RNAs as novel components in the TP53 pathway
Xu et al. The therapeutic potential of a novel non-ATP competitive FGFRlinhibitor on gastric cancer
Weng et al. miRNA-409-3p inhibits tumor growth, vascularization and metastasis by targeting angiogenin